In 2015, Brown et al. conducted the first CAR-T trial for GBM and targeted IL-13Rα2—a protein associated with poor prognosis and expressed in up to 50% of GBM cases—in 3 patients with recurrent disease.42 The patients, who consisted of 3 adults with recurrent or refractory grade III or IV gliomas that were amenable to resection, received 12 local infusions of IL-13Rα2-specific CD8 + T-cells following resection at the time of recurrence. The gene discussed is IL13RA2; the disease is glioma.